> 数据图表想问下各位网友第四章：按照治疗领域或具体药物类别2026年行业催化剂列表2026-1-2第四章：按照治疗领域或具体药物类别2026年行业催化剂列表4.1 大型制药企业及部分生物技术企业临床催化剂日历 - 小核酸领域图44：全球小核酸领域主要靶点（及相关联竞争药物）全球临床项目催化剂大致时间表2026 年 1 月 5 日（星期一）NovartisNVSPelacarsen/ TQJ230 Inclisiran/ 英克司兰first-in-class Lp(a) ASO, QWfirst-in-class PCSK9 siRNA, Q6MAbelacimabHuman mAb targeting Factor XI & XIaHORIZON(a) CVOT Outcomes trial in patients with established ASCVD ORION-4 CVRR-LDLC CVOT Outcomes trial VICTORION-2 PREVENT (V2P) stroke prevention in Atrial Fibrillation (SPAF) cancer-associated thrombosisPh3 readout Ph3 readout PDUFA PDUFAPh3 completion/readout2026-FebIL-6R mAbAtherosclerotic cardiovascular disease (ASCVD) Ph3 initiatefirst-in-class miR-17 inhibitorautosomal dominant polycystic kidney disease (ADPKD)Ph3 initiateAOC (Antibody-Oligo conjugate) DMPKmyotonic dystrophy type 1 (DM1)Ph3 completion/readout2026Pacibekitug/ TZLS-501farabursen/ RGLS 8429del-desiran/ AOC 1001Olpasiran/ AMG8902026H2/2027 2027 2026Q4 2026Q4202620262026-Dec2025YE/ 2026Q1 2026Q1 2026H2 2026+20262026H1Novartis/ AnthosNovartis/ TourmalineNovartis/ RegulusNovartis/ AvidityAmgenAmgenRegeneron/ AlnylamSilence TherapeuticsSilence TherapeuticsAstraZenecaNVSNVSNVSNVSAMGNREGN/ ALNYSLNSLNAZNAlnylamAlnylamAlnylamALNYALNYALNY资料来源：招商证券（香港）整理first Lp(a) targeting siRNA, sc Q3WOCEAN(a)-Outcomes established ASCVDtrialin patients withPh3 readoutAMGNMariTidelong-acting, peptide-antibody conjugate QMPhase 2 study in obesityPh2 part B readoutCemdisiranC5 targeting siRNAMyasthenia Gravis Geographic Atrophy Paroxysmal Nocturnal HemoglobinuriaPDUFA Phase 3 initial data Cohort B study enrollingZerlasiranLp(a) targeting siRNAHigh Lp(a)potential collaboration eventDivesiranTMPRSS6 targeting siRNAPolycythemia VeraPh2 SANRECO topline result2026Q3Laroprovstat/ AZD0780Lp(a) small moleculeAZURE-LDL CVOT Outcome trialPh3 readout2027-MarArrowheadARWRARO - INHBEINHBE targeting siRNAMono treatment or combo with TirzepatidePhI/IIa part 1 (SAD/MAD) data2025 YEArrowheadARWRARO - ALK7ALK7 targeting siRNAbody weight lean mass reduction combo with TirzepatidePhI/IIa SAD dataMivelsiranAPP targeting siRNAAlzheimer diseasePh2 initiateAdipose targeting ACVR1C siRNAIND filing and Ph1 initiation2026H1muscle targeting siRNAGenetic muscle diseaseIND filing and Ph1 initiation2026H1彭博终端报告下载：NH CMS <GO>32招商证券(香港)能源矿产
